Pfizer director Ronald E. Blaylock acquires $499,072 in stock

On February 13, Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The transaction was valued at a total of $499,072, with each share priced at $25.65. The purchase comes as Pfizer trades near its 52-week low, with InvestingPro analysis indicating the stock is currently undervalued. The company maintains a robust 6.71% dividend yield and carries a GOOD financial health score. Following this acquisition, Blaylock's direct ownership of Pfizer's stock increased to 27,707 shares. Additionally, Blaylock holds 4,750 shares indirectly through a trust. This recent purchase highlights Blaylock's continued investment in the pharmaceutical giant, which commands a market capitalization of $144.56 billion. For deeper insights into insider trading patterns and comprehensive analysis, investors can access Pfizer's detailed Pro Research Report, available exclusively on InvestingPro.

In other recent news, Pfizer Inc. has been in the spotlight for various developments. The company's ADCETRIS regimen for lymphoma treatment has received FDA approval, marking a significant milestone in the treatment of certain types of relapsed or refractory large B-cell lymphoma. This approval was based on the Phase 3 ECHELON-3 trial, which demonstrated a 37% reduction in the risk of death for patients treated with the ADCETRIS regimen.

Pfizer also announced positive results from its Phase 3 BREAKWATER study of BRAFTOVI in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation. The study showed significant improvement in progression-free survival and overall survival.

With regard to analyst notes, Jefferies raised Pfizer's stock price target to $34, maintaining a Buy rating, while Goldman Sachs reduced its price target from $33 to $32, still maintaining a Buy rating. These adjustments came following Pfizer's recent earnings report and the release of Pfizer's abstract on mevrometostat from the American Society of Clinical Oncology Genitourinary symposium.

In other developments, the Senate confirmed Robert F. Kennedy Jr. as Secretary of Health and Human Services, a move that has negatively impacted vaccine stocks, including Pfizer's. These are the recent highlights in Pfizer's journey, reflecting the company's continuous efforts in the healthcare sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.